A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies
To establish a safe dose of the study drug (AZD5363) by gathering information on how well it is tolerated, any potential side effects it may cause, and collecting data about how your cancer responds to the drug.
Breast, cervical, endometrial, or ovarian cancer, or other solid tumors.
1. Female or male 18 years or older.
2. Malignant breast, cervical, endometrial, or ovarian cancer, or other solid tumors, with either a PIK3CA or AKT1 mutation.
3. Cannot have diabetes.
4. Other criteria also apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until disease progression, unacceptable side effects, or participant's decision to withdraw from the study.
Knight Clinical Trials Information Line
$45 per visit